Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus RETET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus RETET.
DOXYCHEL vs RETET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
RETET is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors, thereby blocking estrogen-mediated signaling in target tissues.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
No standard dosing available; RETET is not a recognized therapeutic agent. Please verify drug name.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Terminal elimination half-life 18-24 hours in healthy adults; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Renal: 70-80% unchanged; Fecal: 10-15%; Biliary: <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic